Concr is pleased to announce that it has achieved ISO/IEC 27001:2022 certification – the internationally recognised standard for information security management systems.
This milestone affirms Concr’s commitment to robust information governance and a strong security posture across its operations, ensuring the confidentiality, integrity, and availability of both the sensitive data entrusted to us and the data we generate — including clinical and molecular patient data processed through our FarrSight® platform and integrated services.
“Achieving ISO 27001 certification is a significant milestone for Concr,” said Emre Misirlioglu, Chief Operating Officer at Concr. “It reinforces the trust we’ve built with our partners, that we meet the highest standards when handling sensitive health and research data. We’ve invested purposefully in secure infrastructure and governance to ensure that FarrSight® and the underlying technology continue to iterate responsibly, in step with emerging frameworks for AI/ML transparency, validation, and data protection. As the regulatory landscape for novel computational tools in life sciences and healthcare continues to evolve, we see this certification as a critical foundation of our commitment to deliver impact with rigour and integrity.”
The certification was issued by BSI following a comprehensive audit process, covering Concr’s global operations across the UK and Australia. As the UK’s national standards body and a leading Notified and Approved Body for medical technologies, BSI was selected for its rigorous approach, ensuring Concr’s controls were assessed against the highest standards.
As Concr continues to empower translational research and early clinical development through its integrated suite of offerings –– including pre-clinical efficacy predictions, biomarker discovery, in-silico trial simulations, and next-generation digital twins –– secure-by-design infrastructure and governance remain core to our ability to scale responsibly and work confidently with partners across healthcare, research, and industry.
This work was partly supported by Innovate UK as part of the AI-VISION trial (NCT06409221), enabling robust governance when working with sensitive patient-derived data in AI-driven oncology research.
Back
LinkTree